Regeneron Pharmaceuticals’s Parabilis Medicines Inc PBLS Stock Holding History

Regeneron Pharmaceuticals’s Portfolio PBLS Stock Details PBLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114M	Buy	+4,166,666	New	+$115M	64.35%	1

Other funds holding PBLS

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

PAP

Persistent Asset Partners Hong Kong $335M AUM 275.57% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

BIA

Bell Investment Advisors Oakland, California $681M AUM 18.36% 1-Year Est. Return

Regeneron Pharmaceuticals's PBLS Position: Q2 2026 in Review

Regeneron Pharmaceuticals opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 4,166,666 shares worth $114M. The stake represents 64.35% of the portfolio and ranks #1 among its holdings.

17 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

Regeneron Pharmaceuticals held 4,166,666 shares of Parabilis Medicines Inc worth $114M as of Q2 2026.
Parabilis Medicines Inc was a new Regeneron Pharmaceuticals position in Q2 2026.
Parabilis Medicines Inc made up 64.35% of Regeneron Pharmaceuticals's portfolio in Q2 2026, its #1 holding.
17 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on Regeneron Pharmaceuticals's 13F filing for Q2 2026, filed 7 Aug 2026.